|
|
Exact Sciences Corporation - Comparative Business Analysis Snapshot
Business Description
Exact Sciences Corporation. The Group's principal activities are to develop and commercialize proprietary DNA based tests for the early detection of cancer and other types of common cancers. PreGen-Plus utilizes PreGen technologies to isolate the minute amounts of human DNA shed from the colon into stool and then identifies mutations in DNA shed from abnormal cells indicative of colorectal cancer and pre-cancerous lesions. It also offers PreGen-Plus through LabCorp, in the United States with 35 primary laboratories and over 1,600 patient service centers. LabCorp is the exclusive licensee, in the United States and Canada, of the technology that surrounds PreGen-Plus.
Competitor Analysis
This analysis compares Exact Sciences Corporation with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
